– UK, London / CANADA, Vancouver – Small Pharma Inc. (TSX: DMT), a neuro-pharmaceutical company focused on psychedelic-assisted therapies, today announced the appointment of Board member Lyne Fortin as non-executive independent chair of its Board of Directors.
“With 35 years of experience across Big Pharma and biotech, including 26 years at Merck, Lyne has already proven invaluable as an independent director and I couldn’t be happier to welcome her as Chair. Her in-depth experience will continue to be invaluable to Small Pharma as we look to build on the strong progress we have made this year,” said CEO, Peter Rands.
About Lyne Fortin
Ms. Fortin has served as a director of the Company since April 29, 2021 and will continue to serve in her roles as chair of the Compensation Committee and the Corporate Governance and Nominating Committee and as a member of the Audit Committee.
Lyne Fortin, new Board Chair said: “I am honored to be Chair of the Board of Small Pharma as the growing burden of mental health is in need of ground-breaking solutions. Small Pharma represents the perfect match of a clearly differentiated program in psychedelic research, with the drive of a strong and passionate team to deliver tangible results.”
About Small Pharma
Small Pharma is a neuro-pharmaceutical company specialized in IP-led development of novel treatments for mental health conditions, with a focus on depression. Small Pharma initiated a clinical program into N,N-dimethyltryptamine assisted therapy in February 2021. This program includes a Phase I/IIa trial on its lead candidate alongside development of a robust pipeline of proprietary preclinical assets.
For more information: https://www.smallpharma.com